Forest Laboratories and Pierre Fabre Medicament Announce Positive Phase III Results For Levomilnacipran in Patients with Major Depressive Disorder
Forest Laboratories, Inc. (NYSE: FRX) and Pierre Fabre Medicament today announced positive top-line results in a Phase III clinical trial of levomilnacipran, an investigational agent for the treatment of adults with major depressive disorder. Treatment with levomilnacipran significantly reduced depression symptoms in patients with MDD compared to placebo, as early as week one and at each subsequent visit as measured by the Montgomery-Asberg Depression Rating Scale-Clinician Rated (MADRS-CR).
This is the second, positive placebo-controlled Phase III study in this population. Further analyses of the data are ongoing. Results from an additional placebo-controlled Phase III fixed-dose study are expected in Spring 2012.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.